Key highlights

  • Island Pharmaceuticals shares were down 9.23% at $0.295 during the 10 November 2026 trading session.
  • Surgical preparations for 22 non-human primates have started at USAMRIID in Maryland.
  • Galidesivir dosing is expected to begin in early December 2026.

Island Pharmaceuticals Ltd (ASX:ILA) fell 9.23% to $0.295 during the 10 November 2026 trading session. The S&P/ASX 200 was higher by 1.34%, or 121.20 points, at 9,150.90 over the same session. Island is an Australian antiviral Drug Development and biodefence company. Its latest update was released on 4 November 2026 and covered the start of surgical preparations for a Galidesivir dose optimisation study targeting Marburg virus disease.

Study preparations at USAMRIID

Island said that scheduled surgical preparations for 22 non-human primates allocated to the study have commenced at the United States Army Medical Research Institute of Infectious Diseases at Fort Detrick, Maryland. The company described the step as a significant operational milestone, following the completion of primate screening in October.

The procedures form part of the established protocol and will support Day 0 Marburg infection and frequent data collection. The animals will recover before dosing begins.

Study design and regulatory pathway

The study will involve 20 primates, with two reserve animals. It will assess Galidesivir at varying dose levels and treatment start times against the Angola strain of Marburg virus. The results will inform the design of a planned pivotal efficacy study.

The work supports Island's development under the US Food and Drug Administration's Animal Rule pathway, which can apply where human efficacy studies are not ethical or feasible.

Sector context

Antiviral and biodefence companies depend on government-linked programs and on the design of their animal studies. Share prices in the sector often respond to updates on study timing and regulatory path. Island's shares trade near 30 cents, and the broader market was higher during the session.

Risks

Dosing timelines depend on the completion of surgical preparations and recovery, and any delay could move the study schedule. Results from animal studies may not translate to human efficacy.

The company's path depends on acceptance of the Animal Rule approach, which would need to be supported by its data package.

What to watch ahead

Investors will be looking for confirmation that dosing has started in early December, the study results and the timetable for the planned pivotal efficacy study.

Final Word

Island's Trading session fall came as investors weighed an update on surgical preparations for its Marburg study. The start of dosing and eventual study results will shape the company's regulatory progress.